Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Clinical trial NCT03816345 · RECRUITING

Trial details

NCT number: NCT03816345
Sponsor: National Cancer Institute (NCI)
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Autoimmune Disease Crohn Disease Dermatomyositis Hematopoietic and Lymphoid Cell Neoplasm Inflammatory Bowel Disease Malignant Solid Neoplasm Multiple Sclerosis Psoriasis Psoriatic Arthritis Rheumatoid Arthritis Sjogren Syndrome Systemic Lupus Erythematosus

Start date: 2019-07-16
Primary completion: 2028-03-30
Enrollment: 300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.